News related to Crestor (Rosuvastatin) and/or conditions it is approved for
Study Might Prompt Expanded Use Of Crestor, Increase U.S. Health Care Costs By $10B Annually, Analysis Finds
Source: Statins News From Medical News Today [2008.11.12]
Use of the cholesterol medication Crestor, manufactured by AstraZeneca, to prevent cardiovascular events in patients who do not have high cholesterol levels but have high levels of C-reactive protein would increase U.S. health care costs by $10 billion annually, according to an analysis released on Monday,
Crestor Can Reduce Risk For Cardiovascular Events In Patients With High Levels Of Protein, Study Finds
Source: Cholesterol News From Medical News Today [2008.11.11]
The cholesterol medication Crestor, manufactured by AstraZeneca, can reduce by about half the risk for heart attack, stroke and death among patients who do not have high cholesterol levels but tested positive for high levels of a protein linked with increased risk for heart attack, according to a study presented Sunday at the annual meeting of the
Crestor FAQ: New Benefits for Statins
Source: MedicineNet Cholesterol Specialty [2008.11.11]
Title: Crestor FAQ: New Benefits for Statins
Category: Health News
Created: 11/11/2008
Last Editorial Review: 11/11/2008
CRESTOR Demonstrates Dramatic CV Risk Reduction In A Large Statin Outcomes Study
Source: Cholesterol News From Medical News Today [2008.11.10]
New data from the JUPITER study demonstrated that CRESTOR(R) (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p
Statins May Benefit People With Low Cholesterol
Source: Statins News From Medical News Today [2008.11.10]
An international trial found that the cholesterol busting drug rosuvastatin reduced heart attack and stroke in men and women with low cholesterol who had high levels of C-reactive protein but who were otherwise classed as healthy, and experts suggested this could be a class effect of all statins and not just rosuvastatin, which is marketed by AstraZeneca as Crestor.
Rosuvastatin Label Change in EU Indicates Risk of Myopathy
Source: Medscape Pharmacotherapy Headlines [2004.06.10]
The European Union labeling changes reflect risk of muscle toxicity associated with increased drug levels.
Medscape
Yael Waknine
Dramatic JUPITER Findings Fail To Sway Prescribing Behavior, Poll Shows
Source: Cardiovascular / Cardiology News From Medical News Today [2008.11.26]
JUPITER, a clinical trial suggesting rosuvastatin may lower the cardiovascular risk of healthy patients with elevated CRP, should not prompt universal statin use in older adults, according to a national poll directed at health professionals. Some 1,212 participants took part in the online poll conducted by medical news site MedPage Today LLC (http://www.MedPageToday.com).
|
